The Hypothesis

I suspect that Acarbose doesn't just extend lifespan through systemic metabolic changes. Instead, it triggers a portal-venous, sex-specific AMPK activation mechanism fueled by Muribaculaceae-derived propionate. The sex gap here is striking: females already maintain higher hepatic mitochondrial coupling and estrogen-driven AMPK activity, which likely makes this extra SCFA-driven boost redundant. Males, however, struggle with higher baseline hepatic lipid loads and inflammatory insulin resistance, allowing them to reap major longevity rewards from the propionate-mediated activation of the LKB1-AMPK axis right in the portal vein.

Mechanistic Reasoning

1. Portal-First Priority: Researchers often focus on systemic SCFA levels, but concentrations in the portal vein are significantly higher. I believe Muribaculaceae-derived propionate acts as an allosteric modulator for portal-resident AMPK. This isn't just a broad metabolic fix; it’s a localized signaling event that flips hepatic metabolism from lipogenesis to beta-oxidation before the liver has a chance to metabolize those SCFAs [https://pmc.ncbi.nlm.nih.gov/articles/PMC5380489/].
2. The Sex-Dimorphic Threshold: In aging male models, androgen-driven inhibition of hepatic AMPK is well-documented. Acarbose likely overrides this by boosting local portal propionate. Females don't see the same benefit because their estrogen signaling already keeps AMPK phosphorylation at a higher baseline, creating a 'ceiling effect' that leaves little room for further improvement [https://pmc.ncbi.nlm.nih.gov/articles/PMC6567620/].
3. Dietary Dependency as a Stoichiometric Switch: When Acarbose fails in low-starch diets, it’s not just a substrate issue. It's a failure to hit the stoichiometric threshold needed to flood the portal vein with enough propionate to trigger that specific signaling pathway.

Experimental Validation

We can test this through three specific approaches:

• Portal vs. Systemic Infusion: Using specialized catheters to deliver propionate directly into the portal vein versus systemic circulation. If the longevity benefit relies on portal-hepatic signaling, portal-only infusion should mimic the male-specific Acarbose phenotype at lower total doses.
• LKB1-Specific Knockouts: By using liver-specific LKB1-knockout mice, we can check if the effect vanishes. If this hypothesis is right, these males shouldn't gain any longevity from Acarbose, since the drug’s primary 'sensor' for the SCFA-shift will be missing [https://synapse.patsnap.com/article/what-is-the-mechanism-of-acarbose].
• Microbiome Transfer (FMT): Transplanting microbiota from Acarbose-treated male donors into untreated, aged males on a high-starch diet. If the SCFA-portal-AMPK axis is truly causal, we should see a spike in hepatic AMPK phosphorylation and better glucose handling even without the drug, offering strong proof of microbiome-mediated longevity [https://fastlifehacks.com/life-extending-drugs-from-itp-trials/].

Shifting our focus to the portal-venous interface moves us away from vague correlations and toward a mechanistic understanding of how dietary starch actually shapes the aging process.